Kobayashi, Taku
Hoshi, Masato
Yuasa, Akira
Arai, Shoko
Ikeda, Mitsunobu
Matsuda, Hiroyuki
Kim, Seok-Won
Hibi, Toshifumi
Article History
Accepted: 12 February 2023
First Online: 8 March 2023
Declarations
:
: Pfizer Japan Inc. was the only direct sponsor of this study, and fees were paid to IQVIA Solutions Japan K.K.
: The authors declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TK received lecture fees from AbbVie GK, Activaid, Alfresa Pharma Corporation, Gilead Sciences, Nippon Kayaku Co., Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and EA Pharma. TK received consulting fees from Takeda Pharmaceutical Co., Ltd., Activaid, Alfresa Pharma Corporation, Zeria Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Pfizer Japan Inc., Janssen Pharmaceutical K.K., Thermo Fisher Diagnostics K.K., JIMRO Co., Ltd., Bristol-Myers Squibb, Gilead Sciences, Galapagos, and Eli Lilly Japan K.K. TK received grants from Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Otsuka Holdings, EA Pharma Co., Ltd., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Google Asia Pacific Pte. Ltd., Alfresa Pharma Corporation, and JMDC Inc. MH is a full-time employee of Pfizer Japan Inc. AY and SA are full-time employees of Pfizer Japan Inc., and hold stocks and stock options from Pfizer Inc. MI was a full-time employee of Pfizer Japan Inc. at the time this study was conducted. HM and SWK are full-time employees of IQVIA Solutions Japan K.K. TH received honorarium from Aspen Japan K.K., AbbVie GK., Ferring, Gilead Sciences, Janssen Pharmaceutical K.K., JIMRO Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co, Ltd., Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd. TH received consulting fees from Apo Plus Station, AbbVie GK., Bristol-Myers Squibb, Celltrion, EA Pharma, Eli Lilly Japan K.K., Gilead Sciences, Janssen Pharmaceutical K.K., Kyorin Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nichi-Iko Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Zeria Pharmaceutical Co., Ltd.
: Not applicable. This cost-effectiveness analysis was used to simulate the long-term clinical and economic results of tofacitinib and other biologics based on existing literature findings and completed clinical trials. Moreover, the current research does not involve any studies on human participants or animals directly performed by any of the authors.
: Not applicable.
: Not applicable.
: Except for clinical data and other confidential data associated with modeling and data analysis, all data are available from the corresponding author upon reasonable request.
: Not applicable.
: All named authors take responsibility for the integrity of the work as a whole and have given final approval for this version to be published. All authors conceived and designed the study, populated the model inputs, and reviewed the manuscript.